Galera Therapeutics Analyst Ratings
Galera Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2023 | 11.15% | HC Wainwright & Co. | $6 → $0.3 | Downgrades | Buy → Neutral |
| 08/10/2023 | 85.25% | Piper Sandler | $6 → $0.5 | Downgrades | Overweight → Neutral |
| 07/17/2023 | 2123.05% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 03/22/2023 | 2123.05% | HC Wainwright & Co. | $10 → $6 | Maintains | Buy |
| 02/21/2023 | 2123.05% | Piper Sandler | → $6 | Initiates Coverage On | → Overweight |
| 02/16/2023 | 2493.55% | B of A Securities | $2 → $7 | Upgrades | Underperform → Buy |
| 02/16/2023 | 3605.08% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 05/27/2022 | 641.02% | B of A Securities | → $2 | Downgrades | Neutral → Underperform |
| 12/20/2021 | 7310.15% | Citigroup | $11 → $20 | Maintains | Buy |
| 12/15/2021 | 3605.08% | HC Wainwright & Co. | → $10 | Upgrades | Neutral → Buy |
| 12/15/2021 | 5457.61% | BTIG | → $15 | Upgrades | Neutral → Buy |
| 10/20/2021 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 10/19/2021 | — | BTIG | Downgrades | Buy → Neutral | |
| 12/16/2020 | 5457.61% | Credit Suisse | $9 → $15 | Upgrades | Neutral → Outperform |
| 12/07/2020 | 5457.61% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 11/11/2020 | 3234.57% | Credit Suisse | $8 → $9 | Maintains | Neutral |
| 07/29/2020 | 2864.06% | Credit Suisse | $14 → $8 | Maintains | Neutral |
| 12/02/2019 | 11015.23% | BTIG | → $30 | Initiates Coverage On | → Buy |
| 12/02/2019 | 5457.61% | B of A Securities | → $15 | Initiates Coverage On | → Buy |
| 12/02/2019 | 7310.15% | Citigroup | → $20 | Initiates Coverage On | → Buy |
| 12/02/2019 | 5087.11% | Credit Suisse | → $14 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/16/2023 | 11.15% | HC Wainwright & Co. | 6 美元 → 0.3 美元 | 降级 | 买入 → 中性 |
| 08/10/2023 | 85.25% | 派珀·桑德勒 | 6 美元 → 0.5 美元 | 降级 | 超重 → 中性 |
| 07/17/2023 | 2123.05% | HC Wainwright & Co. | → 6 美元 | 重申 | 购买 → 购买 |
| 03/22/2023 | 2123.05% | HC Wainwright & Co. | 10 美元 → 6 美元 | 维护 | 购买 |
| 02/21/2023 | 2123.05% | 派珀·桑德勒 | → 6 美元 | 启动覆盖开启 | → 超重 |
| 02/16/2023 | 2493.55% | B of A 类证券 | $2 → 7 美元 | 升级 | 跑赢大盘 → 买入 |
| 02/16/2023 | 3605.08% | HC Wainwright & Co. | → 10 美元 | 重申 | → 购买 |
| 05/27/2022 | 641.02% | B of A 类证券 | → 2 美元 | 降级 | 中性 → 跑赢大盘 |
| 2021 年 12 月 20 日 | 7310.15% | 花旗集团 | 11 美元 → 20 美元 | 维护 | 购买 |
| 2021 年 12 月 15 日 | 3605.08% | HC Wainwright & Co. | → 10 美元 | 升级 | 中性 → 买入 |
| 2021 年 12 月 15 日 | 5457.61% | BTIG | → 15 美元 | 升级 | 中性 → 买入 |
| 2021 年 10 月 20 日 | — | HC Wainwright & Co. | 降级 | 买入 → 中性 | |
| 10/19/2021 | — | BTIG | 降级 | 买入 → 中性 | |
| 2020 年 12 月 16 日 | 5457.61% | 瑞士信贷 | 9 美元 → 15 美元 | 升级 | 中性 → 跑赢大盘 |
| 12/07/2020 | 5457.61% | HC Wainwright & Co. | → 15 美元 | 启动覆盖开启 | → 购买 |
| 11/11/2020 | 3234.57% | 瑞士信贷 | 8 美元 → 9 美元 | 维护 | 中立 |
| 07/29/2020 | 2864.06% | 瑞士信贷 | 14 美元 → 8 美元 | 维护 | 中立 |
| 12/02/2019 | 11015.23% | BTIG | → 30 美元 | 启动覆盖开启 | → 购买 |
| 12/02/2019 | 5457.61% | B of A 类证券 | → 15 美元 | 启动覆盖开启 | → 购买 |
| 12/02/2019 | 7310.15% | 花旗集团 | → 20 美元 | 启动覆盖开启 | → 购买 |
| 12/02/2019 | 5087.11% | 瑞士信贷 | → 14 美元 | 启动覆盖开启 | → 中立 |
What is the target price for Galera Therapeutics (GRTX)?
Galera Therapeutics（GRTX）的目标价格是多少？
The latest price target for Galera Therapeutics (NASDAQ: GRTX) was reported by HC Wainwright & Co. on August 16, 2023. The analyst firm set a price target for $0.30 expecting GRTX to rise to within 12 months (a possible 11.15% upside). 7 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年8月16日公布了Galera Therapeutics（纳斯达克股票代码：GRTX）的最新目标股价。这家分析公司将目标股价定为0.30美元，预计GRTX将在12个月内上涨至11.15％（可能上涨11.15％）。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Galera Therapeutics (GRTX)?
分析师对Galera Therapeutics（GRTX）的最新评级是多少？
The latest analyst rating for Galera Therapeutics (NASDAQ: GRTX) was provided by HC Wainwright & Co., and Galera Therapeutics downgraded their neutral rating.
Galera Therapeutics（纳斯达克股票代码：GRTX）的最新分析师评级由HC Wainwright & Co. 提供，Galera Therapeutics下调了中性评级。
When is the next analyst rating going to be posted or updated for Galera Therapeutics (GRTX)?
Galera Therapeutics（GRTX）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galera Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galera Therapeutics was filed on August 16, 2023 so you should expect the next rating to be made available sometime around August 16, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Galera Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Galera Therapeutics的最后一次评级是在2023年8月16日提交的，因此你应该预计下一个评级将在2024年8月16日左右公布。
Is the Analyst Rating Galera Therapeutics (GRTX) correct?
分析师对 Galera Therapeutics (GRTX) 的评级正确吗？
While ratings are subjective and will change, the latest Galera Therapeutics (GRTX) rating was a downgraded with a price target of $6.00 to $0.30. The current price Galera Therapeutics (GRTX) is trading at is $0.27, which is out of the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的Galera Therapeutics（GRTX）评级被下调，目标股价为6.00美元至0.30美元。Galera Therapeutics（GRTX）目前的交易价格为0.27美元，超出了分析师的预测区间。